Cardio3 BioSciences

General presentation

"Cardio3 BioSciences is a leading Belgian biotechnology company specialising in stem cell-based therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure®, is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs.
Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology from Mayo Clinic,
C-Cure® allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company's strategy is to drive the clinical development of C-Cure® and to market the product itself in major territories. Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium."

Domains of specialization

• Biotechnologies